

IN THE CLAIMS:

Claims 1-4 (**cancelled**).

Claim 5 (**previously presented**): A compound as claimed in claim 18 wherein Zb is -O-.

Claim 6 (**previously presented**): A compound as claimed in claim 18 wherein R^{2a} is methoxy.

Claim 7 (**previously presented**): A compound as claimed in claim 18 wherein ring C is a 5-membered heteroaromatic moiety which contains 1-3 heteroatoms selected independently from O, N and S.

Claim 8 (**previously presented**): A compound as claimed in claim 18 wherein R¹ is a phenyl group or a 5-6-membered heteroaromatic group with 1-3 heteroatoms, selected independently from O, S and N, (linked via a ring carbon atom), which phenyl or heteroaromatic group is optionally substituted as defined in claim 18.

Claim 9 (**currently amended**): A compound as claimed in claim 18 wherein R² represents hydroxy, nitro, trifluoromethyl, C₁₋₃alkyl, cyano, amino or R⁵X¹- wherein X¹ is as defined in claim 18 and R⁵ is selected from one of the following eighteen groups:

- 1) C₁₋₄alkyl which may be unsubstituted or substituted with one or more fluorine atoms, or C₂₋₄alkyl which may be unsubstituted or substituted with 1 or 2 groups selected from hydroxy and amino;
- 2) C₂₋₃alkylX²COR¹¹- ζ wherein X² is as defined in claim 18 and R¹¹ represents -NR¹³R¹⁴ or -OR¹⁵- ζ wherein R¹³, R¹⁴ and R¹⁵ which may be the same or different are each C₁₋₂alkyl or C₁₋₂alkoxyethyl);
- 3) C₂₋₄alkylX³R¹⁶- ζ wherein X³ is as defined in claim 18 and R¹⁶ is a group selected from C₁₋₃alkyl, cyclopentyl, cyclohexyl, pyrrolidinyl and piperidinyl which group is

- linked to X^3 through a carbon atom and which C_{1-3} alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C_{1-2} alkoxy and which cyclopentyl, cyclohexyl, pyrrolidinyl or piperidinyl group may carry one substituent selected from oxo, hydroxy, halogeno, C_{1-2} alkyl, C_{1-2} hydroxyalkyl and C_{1-2} alkoxy);
- 4) $C_{2-3}alkylX^4C_{2-3}alkylX^5R^{22}$ (wherein X^4 and X^5 are as defined in claim 18 and R^{22} represents hydrogen or C_{1-3} alkyl);
 - 5) $C_{1-4}alkylR^{59}$ (wherein R^{59} is a group selected from pyrrolidinyl, piperazinyl, piperidinyl, 1,3-dioxolan-2-yl, 1,3-dioxan-2-yl, 1,3-dithiolan-2-yl and 1,3-dithian-2-yl, which group is linked to C_{1-4} alkyl through a carbon atom and which group may carry 1 or 2 substituents selected from oxo, hydroxy, halogeno, C_{1-3} alkyl, C_{1-3} hydroxyalkyl, C_{1-3} alkoxy, C_{1-2} alkoxy C_{1-3} alkyl and C_{1-2} alkylsulphonyl C_{1-3} alkyl) or $C_{2-4}alkylR^{60}$ (wherein R^{60} is a group selected from morpholino, thiomorpholino, pyrrolidin-1-yl, piperazin-1-yl and piperidino which group may carry 1 or 2 substituents selected from oxo, hydroxy, halogeno, C_{1-3} alkyl, C_{1-3} hydroxyalkyl, C_{1-3} alkoxy, C_{1-2} alkoxy C_{1-3} alkyl and C_{1-2} alkylsulphonyl C_{1-3} alkyl);
 - 6) $C_{3-4}alkenylR^{61}$ (wherein R^{61} represents R^{59} or R^{60} as defined herein);
 - 7) $C_{3-4}alkynylR^{61}$ (wherein R^{61} represents R^{59} or R^{60} as defined herein);
 - 8) R^{29} (wherein R^{29} is as defined in claim 18);
 - 9) $C_{1-4}alkylR^{29}$ (wherein R^{29} is as defined in claim 18);
 - 10) $1-R^{29}prop-1-en-3-yl$ or $1-R^{29}but-2-en-4-yl$ (wherein R^{29} is as defined in claim 18 with the proviso that when R^5 is $1-R^{29}prop-1-en-3-yl$, R^{29} is linked to the alkenyl group via a carbon atom);
 - 11) $1-R^{29}prop-1-yn-3-yl$ or $1-R^{29}but-2-yn-4-yl$ (wherein R^{29} is as defined in claim 18 with the proviso that when R^5 is $1-R^{29}prop-1-yn-3-yl$, R^{29} is linked to the alkynyl group via a carbon atom);
 - 12) $C_{1-5}alkylX^6R^{29}$ (wherein X^6 and R^{29} are as defined in claim 18);
 - 13) $1-(R^{29}X^7)but-2-en-4-yl$ (wherein X^7 and R^{29} are as defined in claim 18);
 - 14) $1-(R^{29}X^8)but-2-yn-4-yl$ (wherein X^8 and R^{29} are as defined in claim 18);
 - 15) $C_{2-3}alkylX^9C_{1-2}alkylR^{29}$ (wherein X^9 and R^{29} are as defined in claim 18);

16) R^{28} ~~—~~ wherein R^{28} is as defined in claim 18);

17) $C_{2-3}alkylX^9C_{1-2}alkylR^{28}$ ~~—~~ wherein X^9 and R^{28} are as defined in claim 18); and

18) $C_{2-3}alkylR^{54}C_{1-2}alkylX^9R^{55}$ ~~—~~ wherein X^9 , R^{54} and R^{55} are as defined in claim 18);

and additionally wherein any $C_{1-5}alkyl$, $C_{2-5}alkenyl$ or $C_{2-5}alkynyl$ group in R^5X^1 may bear one or more substituents selected from hydroxy, halogeno and amino.

Claim 10 (**previously presented**): A compound as claimed in claim 18 wherein R^2 represents 2-methoxyethoxy, 2-(2-methoxyethoxy)ethoxy, 3-methoxypropoxy, 2-methylsulphonylethoxy, 3-methylsulphonylpropoxy, 2-(tetrahydropyran-4-yloxy)ethoxy, 3-(tetrahydropyran-4-yloxy)propoxy, 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 2-(imidazol-1-yl)ethoxy, 3-(imidazol-1-yl)propoxy, 2-(1,1-dioxothiomorpholino)ethoxy, 3-(1,1-dioxothiomorpholino)propoxy, 2-(1,2,3-triazol-1-yl)ethoxy, 3-(1,2,3-triazol-1-yl)propoxy, 2-(N-methoxyacetyl-N-methylamino)ethoxy, 3-(N-methoxyacetyl-N-methylamino)propoxy, N-methylpiperidin-3-ylmethoxy, 4-(pyrrolidin-1-yl)but-2-en-yloxy, 2-(2-oxopyrrolidin-1-yl)ethoxy, 3-(2-oxopyrrolidin-1-yl)propoxy, 2-(pyrrolidin-1-yl)ethoxy, 3-(pyrrolidin-1-yl)propoxy, 2-(2-(pyrrolidin-1-yl)ethoxy)ethoxy, 2-(2-(4-methylpiperazin-1-yl)ethoxy)ethoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, 2-(methylpiperidino)ethoxy, 3-(methylpiperidino)propoxy, 2-(ethylpiperidino)ethoxy, 3-(ethylpiperidino)propoxy, 2-((2-methoxyethyl)piperidino)ethoxy, 3-((2-methoxyethyl)piperidino)propoxy, 2-((2-methylsulphonyl)ethylpiperidino)ethoxy, 3-((2-methylsulphonyl)ethylpiperidino)propoxy, piperidin-3-ylmethoxy, piperidin-4-ylmethoxy, 2-(piperidin-3-yl)ethoxy, 2-(piperidin-4-yl)ethoxy, 3-(piperidin-3-yl)propoxy, 3-(piperidin-4-yl)propoxy, 2-(methylpiperidin-3-yl)ethoxy, 2-(methylpiperidin-4-yl)ethoxy, 3-(methylpiperidin-3-yl)propoxy, 3-(methylpiperidin-4-yl)propoxy, 2-(ethylpiperidin-3-yl)ethoxy, 2-(ethylpiperidin-4-yl)ethoxy, 3-(ethylpiperidin-3-yl)propoxy, 3-(ethylpiperidin-4-yl)propoxy, 2-((2-methoxyethyl)piperidin-3-yl)ethoxy,

2-((2-methoxyethyl)piperidin-4-yl)ethoxy, 3-((2-methoxyethyl)piperidin-3-yl)propoxy,
3-((2-methoxyethyl)piperidin-4-yl)propoxy,
2-((2-methylsulphonylethyl)piperidin-3-yl)ethoxy,
2-((2-methylsulphonylethyl)piperidin-4-yl)ethoxy,
3-((2-methylsulphonylethyl)piperidin-3-yl)propoxy,
3-((2-methylsulphonylethyl)piperidin-4-yl)propoxy, 1-isopropylpiperidin-2-ylmethyl,
1-isopropylpiperidin-3-ylmethyl, 1-isopropylpiperidin-4-ylmethyl,
2-(1-isopropylpiperidin-2-yl)ethyl, 2-(1-isopropylpiperidin-3-yl)ethyl,
2-(1-isopropylpiperidin-4-yl)ethyl, 3-(1-isopropylpiperidin-2-yl)propyl,
3-(1-isopropylpiperidin-3-yl)propyl, 3-(1-isopropylpiperidin-4-yl)propyl,
3-(4-methylpiperazin-1-yl)propoxy, 1-methylpiperidin-4-ylmethoxy,
1-(2-methylsulphonylethyl)piperidin-4-ylmethoxy,
1-(2-pyrrolidinylethyl)piperidin-4-ylmethoxy,
1-(3-pyrrolidinylpropyl)piperidin-4-ylmethoxy, 1-(2-piperidinylethyl)piperidin-4-ylmethoxy,
1-(3-piperidinylpropyl)piperidin-4-ylmethoxy, 1-(2-morpholinoethyl)piperidin-4-ylmethoxy,
1-(3-morpholinopropyl)piperidin-4-ylmethoxy,
1-(2-thiomorpholinoethyl)piperidin-4-ylmethoxy,
1-(3-thiomorpholinopropyl)piperidin-4-ylmethoxy,
1-(2-azetidinyethyl)piperidin-4-ylmethoxy or 1-(3-azetidinypropyl)piperidin-4-ylmethoxy.

Claim 11 (**previously presented**): A compound as claimed in claim 18 selected from:
4-(5-(4-methoxyphenyl)pyrazol-3-yloxy)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)-
quinazoline,
4-(5-(4-methoxyphenyl)pyrazol-3-yloxy)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)-
propoxy)quinazoline,
6-methoxy-7-(2-(2-methoxyethoxy)ethoxy)-4-(5-phenylpyrazol-3-yloxy)quinazoline,
4-(5-(3-furyl)pyrazol-3-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,
6-methoxy-7-(3-morpholinopropoxy)-4-(5-phenylpyrazol-3-yloxy)quinazoline,
7-(2-(imidazol-1-yl)ethoxy)-6-methoxy-4-(5-phenylpyrazol-3-yloxy)quinazoline,

4-(5-(4-chlorophenyl)pyrazol-3-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,
6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)-4-(5-phenylpyrazol-3-yloxy)-quinazoline,
6-methoxy-7-(2-methoxyethoxy)-4-(5-phenylpyrazol-3-yloxy)quinazoline,
4-(5-(4-methoxyphenyl)pyrazol-3-yloxy)-6-methoxy-7-(2-(1,2,3-triazol-1-yl)ethoxy)-
quinazoline and
4-(5-(4-methoxyphenyl)pyrazol-3-yloxy)-6-methoxy-7-(1-(2-methylsulphonyl)ethyl)-
piperidin-4-ylmethoxy)quinazoline,
and salts thereof.

Claim 12 (**previously presented**): A compound as claimed in claim 18 selected from:
7-(2-methoxyethoxy)-4-(5-phenylpyrazol-3-yloxy)quinazoline,
4-(5-(2-fluorophenyl)pyrazol-3-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,
6-methoxy-7-(3-morpholinopropoxy)-4-(5-(3-nitrophenyl)pyrazol-3-yloxy)quinazoline,
6-methoxy-7-(3-morpholinopropoxy)-4-(5-(4-nitrophenyl)pyrazol-3-yloxy)quinazoline,
6-methoxy-7-(3-morpholinopropoxy)-4-(5-(4-pyridyl)pyrazol-3-yloxy)quinazoline,
4-(5-(4-fluorophenyl)pyrazol-3-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline, and
6-methoxy-7-(2-methoxyethoxy)-4-(5-(4-methoxyphenyl)pyrazol-3-yloxy)quinazoline,
and salts thereof.

Claim 13 (**previously presented**): A method for producing an antiangiogenic and/or
vascular permeability reducing effect in a warm-blooded animal in need of such treatment
which comprises administering to such animal an effective amount of a compound selected
from the group consisting of:

6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)-4-(5-phenylpyrazol-3-ylamino)-quinazoline
and
6,7-dimethoxy-4-(5-phenylpyrazol-3-yloxy)quinazoline
and pharmaceutically acceptable salts thereof.


Claim 14 (**previously presented**): A compound as claimed in any one of claims 18 and 5 to 12 in the form of a pharmaceutically acceptable salt.

Claim 15 (**cancelled**).

Claim 16 (**previously presented**): A pharmaceutical composition which comprises as active ingredient a compound of formula II or a pharmaceutically acceptable salt thereof as claimed in any one of claims 18 and 5 to 12 in association with a pharmaceutically acceptable excipient or carrier.

Claim 17 (**previously presented**): A method for producing an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal in need of such treatment which comprises administering to said animal an effective amount of a compound of formula II as defined in any one of claims 18 and 5 to 12 or a pharmaceutically acceptable salt thereof.

Claim 18 (**previously presented**): A compound of the formula II:



II

wherein:

ring C is a 5-6-membered heterocyclic moiety which may be saturated or unsaturated, which may be aromatic or non-aromatic, and which contains 1-3 heteroatoms selected independently from O, N and S;

Zb is -O- or -S-;

R¹ represents hydrogen, C₁₋₄alkyl, C₁₋₄alkoxymethyl, di(C₁₋₄alkoxy)methyl, C₁₋₄alkanoyl, trifluoromethyl, cyano, amino, C₂₋₅alkenyl, C₂₋₅alkynyl, a phenyl group, a benzyl group or a 5-6-membered heterocyclic group with 1-3 heteroatoms, selected independently from O, S and N, which heterocyclic group may be aromatic or non-aromatic and may be saturated and linked via a ring carbon or nitrogen atom, or unsaturated and linked via a ring carbon atom, and which phenyl, benzyl or heterocyclic group may bear on one or more ring carbon atoms up to 5 substituents selected from hydroxy, halogeno, C₁₋₃alkyl, C₁₋₃alkoxy, C₁₋₃alkanoyloxy, trifluoromethyl, cyano, amino, nitro, C₂₋₄alkanoyl, C₁₋₄alkanoylamino, C₁₋₄alkoxycarbonyl, C₁₋₄alkylsulphanyl, C₁₋₄alkylsulphinyl, C₁₋₄alkylsulphonyl, carbamoyl, N-C₁₋₄alkylcarbamoyl, N,N-di(C₁₋₄alkyl)carbamoyl, aminosulphonyl, N-C₁₋₄alkylaminosulphonyl, N,N-di(C₁₋₄alkyl)aminosulphonyl, C₁₋₄alkylsulphonylamino, C₁₋₄alkylamino, C₁₋₄hydroxyalkyl, C₁₋₄aminoalkyl, C₁₋₄haloalkyl, C₁₋₄hydroxyalkoxy, carboxy and a saturated heterocyclic group selected from morpholino, thiomorpholino, pyrrolidinyl, piperazinyl, piperidinyl imidazolidinyl and pyrazolidinyl, which saturated heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, C₁₋₃alkyl, C₁₋₃alkoxy, C₁₋₃alkanoyloxy, trifluoromethyl, cyano, amino, nitro and C₁₋₄alkoxycarbonyl; and additionally R¹ may represent carboxy, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₃alkyl, or phenylC₂₋₄alkyl wherein the phenyl moiety may bear up to 5 substituents selected from the list herein defined for a phenyl ring which is directly linked to ring C;

n is an integer from 0 to 5;

m is an integer from 0 to 3;

R² represents hydroxy, cyano, nitro, trifluoromethyl, C₁₋₃alkylsulphanyl, -NR³R⁴, wherein R³ and R⁴, which may be the same or different, each represents hydrogen or C₁₋₃alkyl, or R² represents R⁵X¹-, wherein X¹ represents a direct bond, -O-, -CH₂-, -OCO-, carbonyl, -S-, -SO-, -SO₂-, -NR⁶CO-, -CONR⁷-, -SO₂NR⁸-, -NR⁹SO₂- or -NR¹⁰-, wherein R⁶, R⁷, R⁸, R⁹ and R¹⁰ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl, and R⁵ is selected from one of the following eighteen groups:

- 1) hydrogen or C₁₋₅alkyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, chloro, bromo and amino;
- 2) C₁₋₅alkylX²COR¹¹, wherein X² represents -O- or -NR¹²-, in which R¹² represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl, and R¹¹ represents C₁₋₃alkyl, -NR¹³R¹⁴ or -OR¹⁵, wherein R¹³, R¹⁴ and R¹⁵ which may be the same or different each represents hydrogen, C₁₋₃alkyl, C₄₋₅alkyl or C₁₋₃alkoxyC₂₋₃alkyl;
- 3) C₁₋₅alkylX³R¹⁶, wherein X³ represents -O-, -S-, -SO-, -SO₂-, -OCO-, -NR¹⁷CO-, -CONR¹⁸-, -SO₂NR¹⁹-, -NR²⁰SO₂- or -NR²¹-, wherein R¹⁷, R¹⁸, R¹⁹, R²⁰ and R²¹ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl, and R¹⁶ represents hydrogen, C₁₋₃alkyl, cyclopentyl, cyclohexyl or a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which C₁₋₃alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C₁₋₄alkoxy and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄cyanoalkyl and C₁₋₄alkoxycarbonyl;
- 4) C₁₋₅alkylX⁴C₁₋₅alkylX⁵R²², wherein X⁴ and X⁵, which may be the same or different, are each -O-, -S-, -SO-, -SO₂-, -NR²³CO-, -CONR²⁴-, -SO₂NR²⁵-, -NR²⁶SO₂- or -NR²⁷-, wherein R²³, R²⁴, R²⁵, R²⁶ and R²⁷ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl, and R²² represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl;
- 5) R²⁸, wherein R²⁸ is a 5-6-membered saturated heterocyclic group, linked via carbon or nitrogen, with 1-2 heteroatoms selected independently from O, S and N, which heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkylsulphonylC₁₋₄alkyl and C₁₋₄alkoxycarbonyl;
- 6) C₁₋₅alkylR²⁸, wherein R²⁸ is as defined herein;
- 7) C₂₋₅alkenylR²⁸, wherein R²⁸ is as defined herein;
- 8) C₂₋₅alkynylR²⁸, wherein R²⁸ is as defined herein;

- 9) R^{29} , wherein R^{29} represents a pyridone group, a phenyl group or a 5-6-membered aromatic heterocyclic group, linked via carbon or nitrogen, with 1-3 heteroatoms selected from O, N and S, which pyridone, phenyl or aromatic heterocyclic group may carry up to 5 substituents on an available carbon atom selected from hydroxy, halogeno, amino, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} hydroxyalkyl, C_{1-4} aminoalkyl, C_{1-4} alkylamino, C_{1-4} hydroxyalkoxy, carboxy, trifluoromethyl, cyano, $-CONR^{30}R^{31}$ and $-NR^{32}COR^{33}$, wherein R^{30} , R^{31} , R^{32} and R^{33} , which may be the same or different, each represents hydrogen, C_{1-4} alkyl or C_{1-3} alkoxy C_{2-3} alkyl;
- 10) $C_{1-5}alkylR^{29}$, wherein R^{29} is as defined herein;
- 11) $C_{2-5}alkenylR^{29}$, wherein R^{29} is as defined herein;
- 12) $C_{2-5}alkynylR^{29}$, wherein R^{29} is as defined herein;
- 13) $C_{1-5}alkylX^6R^{29}$, wherein X^6 represents $-O-$, $-S-$, $-SO-$, $-SO_2-$, $-NR^{34}CO-$, $-CONR^{35}-$, $-SO_2NR^{36}-$, $-NR^{37}SO_2-$ or $-NR^{38}-$, wherein R^{34} , R^{35} , R^{36} , R^{37} and R^{38} each independently represents hydrogen, C_{1-3} alkyl or C_{1-3} alkoxy C_{2-3} alkyl, and R^{29} is as defined herein;
- 14) $C_{2-5}alkenylX^7R^{29}$, wherein X^7 represents $-O-$, $-S-$, $-SO-$, $-SO_2-$, $-NR^{39}CO-$, $-CONR^{40}-$, $-SO_2NR^{41}-$, $-NR^{42}SO_2-$ or $-NR^{43}-$, wherein R^{39} , R^{40} , R^{41} , R^{42} and R^{43} each independently represents hydrogen, C_{1-3} alkyl or C_{1-3} alkoxy C_{2-3} alkyl, and R^{29} is as defined herein;
- 15) $C_{2-5}alkynylX^8R^{29}$, wherein X^8 represents $-O-$, $-S-$, $-SO-$, $-SO_2-$, $-NR^{44}CO-$, $-CONR^{45}-$, $-SO_2NR^{46}-$, $-NR^{47}SO_2-$ or $-NR^{48}-$, wherein R^{44} , R^{45} , R^{46} , R^{47} and R^{48} each independently represents hydrogen, C_{1-3} alkyl or C_{1-3} alkoxy C_{2-3} alkyl, and R^{29} is as defined herein;
- 16) $C_{1-3}alkylX^9C_{1-3}alkylR^{29}$, wherein X^9 represents $-O-$, $-S-$, $-SO-$, $-SO_2-$, $-NR^{49}CO-$, $-CONR^{50}-$, $-SO_2NR^{51}-$, $-NR^{52}SO_2-$ or $-NR^{53}-$, wherein R^{49} , R^{50} , R^{51} , R^{52} and R^{53} each independently represents hydrogen, C_{1-3} alkyl or C_{1-3} alkoxy C_{2-3} alkyl, and R^{29} is as defined herein;
- 17) $C_{1-3}alkylX^9C_{1-3}alkylR^{28}$, wherein X^9 and R^{28} are as defined herein; and

18) $C_{1-3}alkylR^{54}C_{1-3}alkylX^9R^{55}$, wherein X^9 is as defined herein and R^{54} and R^{55} are each independently selected from hydrogen, $C_{1-3}alkyl$, cyclopentyl, cyclohexyl and a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which $C_{1-3}alkyl$ group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and $C_{1-4}alkoxy$ and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, $C_{1-4}alkyl$, $C_{1-4}hydroxyalkyl$, $C_{1-4}alkoxy$, $C_{1-4}cyanoalkyl$ and $C_{1-4}alkoxycarbonyl$, with the proviso that R^{54} cannot be hydrogen;


and additionally wherein any $C_{1-5}alkyl$, $C_{2-5}alkenyl$ or $C_{2-5}alkynyl$ group in R^5X^1 may bear one or more substituents selected from hydroxy, halogeno and amino; provided that R^2 is not hydrogen, substituted or unsubstituted $C_{1-5}alkyl$, $C_{1-5}alkoxy$, phenoxy or phenyl $C_{1-5}alkoxy$; and

R^{2a} represents hydrogen, halogeno, $C_{1-3}alkyl$, $C_{1-3}alkoxy$, $C_{1-3}alkylthio$, $-NR^{3a}R^{4a}$, wherein R^{3a} and R^{4a} , which may be the same or different, each represents hydrogen or $C_{1-3}alkyl$, or $R^{5a}(CH_2)_{za}X^{1a}$, wherein R^{5a} is a 5- or 6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, $C_{1-4}alkyl$, $C_{1-4}hydroxyalkyl$ and $C_{1-4}alkoxy$, za is an integer from 0 to 4 and X^{1a} represents a direct bond, $-O-$, $-CH_2-$, $-S-$, $-SO-$, $-SO_2-$, $-NR^{6a}CO-$, $-CONR^{7a}-$, $-SO_2NR^{8a}-$, $-NR^{9a}SO_2-$ or $-NR^{10a}-$, wherein R^{6a} , R^{7a} , R^{8a} , R^{9a} and R^{10a} each independently represents hydrogen, $C_{1-3}alkyl$ or $C_{1-3}alkoxyC_{2-3}alkyl$;

or a salt thereof.


19 (**currently amended**): A process for the preparation of a compound of formula II or salt thereof, as defined in claim 18, which comprises:

(a) the reaction of a compound of the formula III:



(III)


(wherein R^2 and m are as defined in claim 18 and L^1 is a displaceable moiety), with a compound of the formula IV:



(IV)

(wherein ring C, R^1 , Z and n are as defined in claim 18);

- (b) compounds of formula II and salts thereof wherein at least one R^2 is R^5X^1 wherein R^5 is as defined in claim 18 and X^1 is -O-, -S-, -OCO- or -NR¹⁰- (wherein R^{10} independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) may be prepared by the reaction of a compound of the formula V:




(V)

{₂ wherein ring C, Z, R¹, R² and n are as defined in claim 18 and X¹ is as defined herein in this section and s is an integer from 0 to 2} with a compound of formula VI:



{₂ wherein R⁵ is as defined in claim 18 and L¹ is as defined herein};

(c) compounds of the formula II and salts thereof wherein at least one R² is R⁵X¹ wherein R⁵ is as defined in claim 18 and X¹ is -O-, -S-, -OCO- or -NR¹⁰-{₂ wherein R¹⁰ represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl} may be prepared by the reaction of a compound of the formula VII:



(VII)


with a compound of the formula VIII:



{₂ wherein R¹, R², R⁵, ring C, Z and n are as defined in claim 18 and s and L¹ are as defined herein and X¹ is as defined herein in this section};

(d) compounds of the formula II and salts thereof wherein at least one R² is R⁵X¹ wherein X¹ is as defined in claim 18 and R⁵ is C₁₋₅alkylR⁶², wherein R⁶² is selected from one of the following nine groups:

- 1) $X^{10}C_{1-3}alkyl-(\text{---})_2$ wherein X^{10} represents -O-, -S-, -SO₂-, -NR⁶³CO- or -NR⁶⁴SO₂-(\text{---})₂ wherein R⁶³ and R⁶⁴ which may be the same or different are each hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl);
 - 2) NR⁶⁵R⁶⁶-(\text{---})₂ wherein R⁶⁵ and R⁶⁶ which may be the same or different are each hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl);
 - 3) $X^{11}C_{1-5}alkylX^5R^{22}-(\text{---})_2$ wherein X^{11} represents -O-, -S-, -SO₂-, -NR⁶⁷CO-, -NR⁶⁸SO₂- or -NR⁶⁹-(\text{---})₂ wherein R⁶⁷, R⁶⁸, and R⁶⁹ which may be the same or different are each hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and X⁵ and R²² are as defined in claim 18);
 - 4) R²⁸-(\text{---})₂ wherein R²⁸ is as defined in claim 18);
 - 5) $X^{12}R^{29}-(\text{---})_2$ wherein X^{12} represents -O-, -S-, -SO₂-, -NR⁷⁰CO-, -NR⁷¹SO₂-, or -NR⁷²-(\text{---})₂ wherein R⁷⁰, R⁷¹, and R⁷² which may be the same or different are each hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R²⁹ is as defined in claim 18);
 - 6) $X^{13}C_{1-5}alkylR^{29}$, preferably $X^{13}C_{1-3}alkylR^{29}-(\text{---})_2$ wherein X^{13} represents -O-, -S-, -SO₂-, -NR⁷³CO-, -NR⁷⁴SO₂- or -NR⁷⁵-(\text{---})₂ wherein R⁷³, R⁷⁴ and R⁷⁵ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R²⁹ is as defined in claim 18);
 - 7) R²⁹-(\text{---})₂ wherein R²⁹ is as defined in claim 18);
 - 8) $X^{14}C_{1-3}alkylR^{28}-(\text{---})_2$ wherein X^{14} represents -O-, -S-, -SO₂-, -NR⁷⁶CO-, -NR⁷⁷SO₂- or -NR⁷⁸-(\text{---})₂ wherein R⁷⁶, R⁷⁷ and R⁷⁸ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R²⁸ is as defined in claim 18); and
 - 9) R⁵⁴C₁₋₃alkylX⁹R⁵⁵-(\text{---})₂ wherein R⁵⁴, R⁵⁵ and X⁹ are as defined in claim 18);
- may be prepared by reacting a compound of the formula IX:



(IX)

(1 wherein X^1 , R^1 , R^2 , ring C, Z and n are as defined in claim 18 and s and L^1 are as defined herein) with a compound of the formula X:



(X)

(1 wherein R^{62} is as defined herein);

- (e) compounds of the formula II and salts thereof wherein one or more of the substituents $(R^2)_m$ is represented by $-NR^{79}R^{80}$, where one (and the other is hydrogen) or both of R^{79} and R^{80} are C_{1-3} alkyl, may be prepared by the reaction of compounds of formula II wherein the substituent $(R^2)_m$ is an amino group and an alkylating agent;
- (f) compounds of the formula II and salts thereof wherein X^1 is $-SO-$ or $-SO_2-$ may be prepared by oxidation from the corresponding compound in which X^1 is $-S-$ or $-SO-$; and when a salt of a compound of formula II is required, reaction of the compound obtained with an acid or base whereby to obtain the desired salt.